BioCentury | Apr 26, 2004
Company News

Cell Signaling Technology Inc., Zeptosens deal

...The companies partnered to combine Cell Signaling's reagents, including phospho-specific antibodies, with Zeptosens' ZeptoMark protein microarray...
...for protein expression analysis and protein activation profiling. Cell Signaling Technology Inc. , Beverly, Mass. Zeptosens AG...
BioCentury | Apr 19, 2004
Company News

Cell Signaling, Zeptosens supply deal

...Mass.) and Zeptosens (Witterswil, Switzerland) partnered to combine Cell Signaling's reagents, including phospho-specific antibodies, with Zeptosens'...
BioCentury | May 13, 2002
Company News

Axxima, Qiagen deal

...oligonucleotide sets and microarrays such as the SensiChip system. SensiChip was developed by QIA and Zeptosens AG...
BioCentury | May 6, 2002
Company News

Qiagen, Axxima chip content deal

...oligonucleotide sets and microarrays such as the SensiChip system. SensiChip was developed by QGENF and Zeptosens...
BioCentury | Aug 13, 2001
Company News

Qiagen, Bayer, Genicon deal

...access to the ZeptoGene Workstation, a DNA microarray technology from QIA. The platform, developed with Zeptosens AG...
BioCentury | Aug 6, 2001
Company News

Qiagen in two microarray deals

...the ZeptoGene Workstation, a DNA microarray technology from Qiagen (QGENF; NMarkt:QIA). The platform, developed with Zeptosens...
BioCentury | Jul 2, 2001
Company News

Qiagen, Aventis deal

...granted AVE limited access to evaluate its ZeptoGene Workstation array platform. QIA's technology, developed with Zeptosens AG...
BioCentury | Jun 28, 2001
Company News

AVE to evaluate QIA's microarray technology

...Aventis (AVE) limited access to evaluate its ZeptoGene Workstation technology platform. QIA's technology, developed with Zeptosens...
BioCentury | May 21, 2001
Financial News

TVM announces first closing for fund

...and hematology disorders; infectious disease and oncology play Pharmasset (Bridgetown, Barbados); and fluorescence-based bioassay company Zeptosens...
BioCentury | Nov 6, 2000
Strategy

Bloodied Aclara says it's not beaten

...property from the '015 patent. Also last week, ACLA licensed a microfluidics patent application from Zeptosens AG...
Items per page:
1 - 10 of 16
BioCentury | Apr 26, 2004
Company News

Cell Signaling Technology Inc., Zeptosens deal

...The companies partnered to combine Cell Signaling's reagents, including phospho-specific antibodies, with Zeptosens' ZeptoMark protein microarray...
...for protein expression analysis and protein activation profiling. Cell Signaling Technology Inc. , Beverly, Mass. Zeptosens AG...
BioCentury | Apr 19, 2004
Company News

Cell Signaling, Zeptosens supply deal

...Mass.) and Zeptosens (Witterswil, Switzerland) partnered to combine Cell Signaling's reagents, including phospho-specific antibodies, with Zeptosens'...
BioCentury | May 13, 2002
Company News

Axxima, Qiagen deal

...oligonucleotide sets and microarrays such as the SensiChip system. SensiChip was developed by QIA and Zeptosens AG...
BioCentury | May 6, 2002
Company News

Qiagen, Axxima chip content deal

...oligonucleotide sets and microarrays such as the SensiChip system. SensiChip was developed by QGENF and Zeptosens...
BioCentury | Aug 13, 2001
Company News

Qiagen, Bayer, Genicon deal

...access to the ZeptoGene Workstation, a DNA microarray technology from QIA. The platform, developed with Zeptosens AG...
BioCentury | Aug 6, 2001
Company News

Qiagen in two microarray deals

...the ZeptoGene Workstation, a DNA microarray technology from Qiagen (QGENF; NMarkt:QIA). The platform, developed with Zeptosens...
BioCentury | Jul 2, 2001
Company News

Qiagen, Aventis deal

...granted AVE limited access to evaluate its ZeptoGene Workstation array platform. QIA's technology, developed with Zeptosens AG...
BioCentury | Jun 28, 2001
Company News

AVE to evaluate QIA's microarray technology

...Aventis (AVE) limited access to evaluate its ZeptoGene Workstation technology platform. QIA's technology, developed with Zeptosens...
BioCentury | May 21, 2001
Financial News

TVM announces first closing for fund

...and hematology disorders; infectious disease and oncology play Pharmasset (Bridgetown, Barbados); and fluorescence-based bioassay company Zeptosens...
BioCentury | Nov 6, 2000
Strategy

Bloodied Aclara says it's not beaten

...property from the '015 patent. Also last week, ACLA licensed a microfluidics patent application from Zeptosens AG...
Items per page:
1 - 10 of 16